Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 29,612 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 29,612 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares in the company, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Personalis Price Performance

Shares of PSNL stock traded down $1.07 during trading on Wednesday, reaching $7.66. The company had a trading volume of 2,105,071 shares, compared to its average volume of 1,067,993. The company has a market capitalization of $679.29 million, a PE ratio of -5.98 and a beta of 1.92. The firm’s 50 day simple moving average is $7.18 and its two-hundred day simple moving average is $6.01. Personalis, Inc. has a one year low of $2.83 and a one year high of $10.95.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $13.31 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Needham & Company LLC raised their price objective on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday. Lake Street Capital restated a “buy” rating and set a $11.00 target price on shares of Personalis in a research report on Wednesday. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. HC Wainwright reaffirmed a “buy” rating and issued a $8.50 target price on shares of Personalis in a research note on Monday, September 8th. Finally, BTIG Research raised their price objective on Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $9.08.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Personalis by 99.3% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 185,036 shares of the company’s stock worth $1,206,000 after acquiring an additional 92,195 shares in the last quarter. AIGH Capital Management LLC raised its stake in Personalis by 4.5% in the third quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after buying an additional 168,143 shares in the last quarter. Howland Capital Management LLC boosted its position in Personalis by 15.9% during the third quarter. Howland Capital Management LLC now owns 330,673 shares of the company’s stock valued at $2,156,000 after purchasing an additional 45,365 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Personalis in the 3rd quarter worth approximately $66,000. Finally, Man Group plc acquired a new stake in shares of Personalis in the 2nd quarter worth $324,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.